Telix Pharmaceuticals (ASX:TLX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Telix Pharmaceuticals (ASX:TLX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - TLX
Notification regarding unquoted securities - TLX
Application for quotation of securities - TLX
Change in substantial holding
Ceasing to be a substantial holder
FDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix secures FDA alignment to advance ProstACT Global Phase 3 prostate cancer trial
Change in substantial holding
Change in substantial holding
Becoming a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Appendix 3Y Change in Director Interest D Gill
Change in substantial holding
Notification regarding unquoted securities - TLX
Appendix 3Y Change in Director Interest - C Behrenbruch
Appendix 3Y Change in Director Interest - M McDonald
Appendix 3Y Change in Director Interest - W Jellison
Appendix 3Y Change in Director Interest - Maria Rivas
Appendix 3Y Change in Director Interest - David Gill
Becoming a substantial holder
Results of Annual General Meeting
Telix Annual General Meeting Presentation
Telix Annual General Meeting Chairman and CEO Addresses
App 3X Initial Director Interests - W Jellison
App 3X Initial Director Interests - M Rivas
App 3X Initial Director Interests - D Gill
Change in substantial holding
Cleansing Notice
Application for quotation of securities - TLX
Notification regarding unquoted securities - TLX
Ceasing to be a substantial holder from CGF
Appendix 3Y Change in Director Interests - C Behrenbruch
Pending Release of Shares from Voluntary Escrow
Change in substantial holding
Webinar - A Next-Gen Portfolio Approach to PSMA Therapy
Notification regarding unquoted securities - TLX
Telix Announces Settlement of US$600M Convertible Bonds
Telix Notice of AGM, Proxy Form and Online Guide
Convertible Bond Cleansing Notice
Becoming a substantial holder from CGF
Change in substantial holding
Notification regarding unquoted securities - TLX
Notification of cessation of securities - TLX
Appendix 3B
Telix Successfully Prices Upsized US$600M Convertible Bonds
Telix upsizes US$600 million convertible bond offering and repurchases majority of 2029 bonds
Telix Investor Presentation April 2026
Telix Pharmaceuticals reports strong 2025 results, advances pipeline, and announces $2.1B Regeneron collaboration
Telix Refinances Convertible Bonds
Telix Pharmaceuticals launches US$550 million convertible bonds offering to refinance existing debt
